What was Stryker's revenue and earnings performance in the first quarter of 2004?

Stryker reported a 22% increase in net sales, reaching $1.035 billion for the first quarter ended March 31, 2004. Net earnings also saw substantial growth, rising 31% to $135.9 million, resulting in diluted earnings per share of $0.33.

What is Stryker's outlook for the full year 2004?

The company is optimistic for 2004, projecting diluted net earnings per share to approximate $1.40 and anticipating net sales growth of around 18%. This growth is expected to be fueled by strong performance in its core business segments, favorable foreign currency exchange rates, and increased revenue from Physical Therapy Services.

How did Stryker's different business segments perform?

Both of Stryker's reportable segments showed strong growth. Orthopaedic Implants sales increased by 23% to $633.1 million, and MedSurg Equipment sales grew by 21% to $341.6 million. Physical Therapy Services also contributed with a 16% increase in revenue.

What significant corporate actions did Stryker announce?

Stryker's stockholders approved an amendment to increase the authorized shares of common stock to one billion. Additionally, the Board of Directors approved a two-for-one stock split, effective May 14, 2004, for stockholders of record on May 3, 2004.

SYK 10-Q Quarterly Report Q1 FY2004 — Revenue, Net Income, EPS

Summary

Stryker Corporation (SYK) reported robust performance for the first quarter ended March 31, 2004, with net sales increasing by 22% year-over-year to $1.035 billion. This growth was driven by strong performance in both the Orthopaedic Implants and MedSurg Equipment segments, with net earnings rising 31% to $135.9 million. The company's outlook for 2004 remains optimistic, projecting diluted net earnings per share of approximately $1.40 and net sales growth of around 18%, supported by favorable foreign currency exchange rates and continued demand for its products. Financially, the company demonstrated solid liquidity and cash flow generation. Despite a planned increase in inventory and accounts receivable associated with business growth, operating cash flow remained significant. Stryker is also actively managing its capital structure, demonstrating efforts to pay down debt and maintain a strong credit facility. Key strategic initiatives include continued investment in research and development for new product launches and a potential for further business acquisitions, signaling a commitment to sustained long-term growth.

Key Highlights

1Net sales increased by 22% to $1.035 billion in Q1 2004, driven by broad-based strength in both Orthopaedic Implants and MedSurg Equipment segments.
2Net earnings grew significantly by 31% to $135.9 million, with diluted EPS rising to $0.33.
3The company provided an optimistic outlook for 2004, expecting diluted EPS of approximately $1.40 and net sales growth of around 18%.
4International sales grew 25% (10% excluding currency impact), indicating strong global demand for Stryker's products.
5Operating income increased by 24% to $193.2 million, demonstrating improved profitability.
6The company declared a two-for-one stock split, effective May 14, 2004, signaling confidence in future performance and aiming to increase stock liquidity.
7Cash flow from operations was $57.9 million, demonstrating continued ability to generate cash despite increased working capital needs.

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2004

Summary

Key Highlights

Frequently Asked Questions